single invest

STipe Therapeutics

STipe Therapeutics focuses on harnessing the innate immune system to battle cancer. The company has developed first-in-class drugs targeting intracellular protein-protein interactions of the STING Pathway; a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders.

 

STipe Therapeutics has been a part of the Accelerace accelerator program, that help startup companies accelerate and scale up their business model and finetune their companies. STipe Therapeutics is one of more than 500 companies that Accelerace already have accelerated.


Related startups


Miiego
Molegro